成都倍特锐玛生物医药科技

Chengdu Betterma Biopharmaceutical Technology is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule and biological therapeutics. As a core R&D subsidiary of Chengdu Better Pharmaceutical, the company targets high-unmet-need areas such as oncology and metabolic diseases. Its lead candidate, BT-1053, is a potent and selective inhibitor of Fibroblast Growth Factor Receptor 4 (FGFR4) designed to treat hepatocellular carcinoma. Betterma operates advanced research facilities in Chengdu, integrating medicinal chemistry, pharmacology, and clinical operations to accelerate its pipeline. The company aims to establish a diverse portfolio of first-in-class and best-in-class drugs for global markets.